Oncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomas
OT-101 is a first-in-class anti-TGF-2 ribonucleic acid ("RNA") therapeutic that has exhibited single agent activity in relapsed/refractory cancer patients in multiple clinical trials.
- OT-101 is a first-in-class anti-TGF-2 ribonucleic acid ("RNA") therapeutic that has exhibited single agent activity in relapsed/refractory cancer patients in multiple clinical trials.
- Therefore, there is an urgent need for therapeutic innovations for treatment of pediatric DMG, explained Fatih Uckun, MD PhD, the Chief Medical Officer of Oncotelic.
- "This is the first of a series of planned clinical trials in pediatric patients with gliomas evaluating clinical benefit while also assessing predictive biomarkers."
- "The groundwork laid down by our successful clinical program in adult gliomas and deep datamining by the team will now help guide the development of OT-101 for pediatric DMG.